Publications by authors named "A W Bollen"
Article Synopsis
- Glioblastoma, despite treatment advancements, has a poor prognosis with less than 2 years median survival due to the unknown reasons for varied treatment responses.
- A study analyzed glioblastoma samples from 106 patients, identifying early genetic changes like TERT promoter mutations, while later alterations varied between initial and recurrent tumors, along with diverse epigenetic changes impacting treatment outcomes.
- Findings indicated that patients with somatic hypermutation post-treatment had better survival rates, and an epigenomic signature linked to DNA methylation changes could predict clinical results, emphasizing the complex evolution of this cancer.
Article Synopsis
- Metastatic Pituitary neuroendocrine tumors (PitNET) are rare and aggressive, making them difficult to treat; however, aggressive behavior is also observed in non-metastatic forms.
- A study at UCSF analyzed samples from multiple patients with different types of aggressive PitNETs, categorizing them according to international neuroendocrine neoplasm criteria and identifying various tumor lineages.
- High rates of disease progression and mortality were noted, along with concerning histopathological and molecular characteristics that could serve as indicators of tumor aggressiveness, suggesting a need for a new grading system.
Introduction: This study used digital intraoral scans to evaluate how clear aligner treatment affects occlusal contacts and to determine the influence of sex and age on contact changes. Results were compared with contact changes that occur during fixed appliance therapy.
Methods: Patients included in this study were treated in a University setting and private practice.
Article Synopsis
- Glioblastoma is a diverse disease, and researchers found a rare subgroup (2%) with unique genetic traits that could help predict treatment responses.
- These tumors have specific mutations linked to Lynch syndrome, appear at a younger median age (50 years), and differ significantly from conventional glioblastomas in genetic and histological characteristics.
- Patients from this subgroup showed an impressive median overall survival of 36.8 months when treated with immune checkpoint inhibitors, highlighting the potential for targeted therapies.